Dataset Information

Role of 18F-FDG PET/CT in patients without known primary malignancy with skeletal lesions suspicious for cancer metastasis.

ABSTRACT: When subjects without a known malignancy present with suspicious skeletal lesions, differential diagnosis and primary cancer identification is important. Here, we investigated the role of FDG PET/CT in this clinical situation.We enrolled 103 patients with no known malignancies who were referred for FDG PET/CT because of bone lesions that were suspicious for cancer metastasis. Each extra-skeletal FDG lesion was categorized as consistent with primary cancer or with metastasis based on the distribution and pattern of all abnormal lesions in the individual.Final diagnosis revealed that bone lesions represented cancer metastasis in 75 patients (72.8%). In the remaining 28 patients (27.2%), they were from other causes including multiple myeloma or lymphoma, malignant primary bone tumor, and benign bone disease. PET/CT indicated a primary cancer in 70 patients (68.0%). This was the correct primary site in 46 cases and the incorrect site in 13 cases (including 6 cases with cancer of unknown primary, CUP). In the remaining 11 cases, the bone lesions were due to other causes. PET/CT did not indicate a primary cancer in 33 patients (32.0%). Of these cases, 17 did not have a primary cancer, 8 had CUP, and 8 had primary cancers that were missed. Thus, PET/CT had a sensitivity of 61.3% and specificity of 60.7% for primary cancer identification in the entire population. Excluding patients with CUP, PET/CT sensitivity was 75.4%. PET/CT also provided information useful for recognizing multiple myeloma and benign bone disease as the cause of the skeletal lesions.In patients without known malignancies with suspected skeletal cancer metastasis, FDG PET/CT can help identify the primary cancer and provide useful information for differential diagnosis.

SUBMITTER: Park SB

PROVIDER: S-EPMC5945029 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Role of 18F-FDG PET/CT in patients without known primary malignancy with skeletal lesions suspicious for cancer metastasis.

Park Soo Bin SB Park Jung Mi JM Moon Seung Hwan SH Cho Young Seok YS Sun Jong-Mu JM Kim Byung-Tae BT Lee Kyung-Han KH

PloS one 20180510 5

<h4>Background</h4>When subjects without a known malignancy present with suspicious skeletal lesions, differential diagnosis and primary cancer identification is important. Here, we investigated the role of FDG PET/CT in this clinical situation.<h4>Methods</h4>We enrolled 103 patients with no known malignancies who were referred for FDG PET/CT because of bone lesions that were suspicious for cancer metastasis. Each extra-skeletal FDG lesion was categorized as consistent with primary cancer or wi ...[more]

PMID: 29746513

Similar Datasets

Project description:The aim of the study was to analyze the use of block sequential regularized expectation maximization (BSREM) with different β-values for the detection of brain metastases in digital fluorine-18 labeled 2-deoxy-2-fluoro-D-glucose (18F-FDG) PET/CT in lung cancer patients. We retrospectively analyzed staging/restaging 18F-FDG PET/CT scans of 40 consecutive lung cancer patients with new brain metastases, confirmed by MRI. PET images were reconstructed using BSREM (β-values of 100, 200, 300, 400, 500, 600, 700) and OSEM. Two independent blinded readers (R1 and R2) evaluated each reconstruction using a 4-point scale for general image quality, noise, and lesion detectability. SUVmax of metastases, brain background, target-to-background ratio (TBR), and contrast recovery (CR) ratio were recorded for each reconstruction. Among all reconstruction techniques, differences in qualitative parameters were analyzed using non-parametric Friedman test, while differences in quantitative parameters were compared using analysis of variances for repeated measures. Cohen's kappa (k) was used to measure inter-reader agreement. The overall detectability of brain metastases was highest for BSREM200 (R1: 2.83 ± 1.17; R2: 2.68 ± 1.32) and BSREM300 (R1: 2.78 ± 1.23; R2: 2.68 ± 1.36), followed by BSREM100, which had lower accuracy owing to noise. The highest median TBR was found for BSREM100 (R1: 2.19 ± 1.05; R2: 2.42 ± 1.08), followed by BSREM200 and BSREM300. Image quality ratings were significantly different among reconstructions (p < 0.001). The median quality score was higher for BSREM100-300, and both noise and metastases' SUVmax decreased with increasing β-value. Inter-reader agreement was particularly high for the detectability of photopenic metastases and blurring (all k > 0.65). BSREM200 and BSREM300 yielded the best results for the detection of brain metastases, surpassing both BSREM400 and OSEM, typically used in clinical practice.

Dataset Information

Role of 18F-FDG PET/CT in patients without known primary malignancy with skeletal lesions suspicious for cancer metastasis.

Publications

Role of 18F-FDG PET/CT in patients without known primary malignancy with skeletal lesions suspicious for cancer metastasis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets